Pelthos Therapeutics Stock Forecast
NYSE: PTHSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 9, 1:32 PM ET
PTHS analyst consensus
Consensus (7 analysts)
strong_buy
Avg. price target
$53.14+156.22%
- Strong buy 1
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 7 Wall Street analysts covering Pelthos Therapeutics (2026-10-09), 7 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $53.14, with a high estimate of $64.00 and a low estimate of $45.00. The average target implies upside of 156.2% from the current price of $20.74.
The spread between the highest and lowest targets is 42.2%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for PTHS.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 14% |
| Buy | 6 | 86% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $45.00 | +116.97% |
| Average target | $53.14 | +156.22% |
| High target | $64.00 | +208.58% |